(Q51047061)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

metastatic renal cell carcinoma

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Nicola Calvani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Franco Morelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Vincenzo Chiuri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Antonio Gnoni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Claudio Scavelli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Palma Fedele

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Laura Orlando

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Vito Lorusso

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Saverio Cinieri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

24 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

578

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23613183%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12032-013-0578-8

29 February 2020

exact match

0 references

cites work

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Immunotherapy for advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Treatment selection in metastatic renal cell carcinoma: expert consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0578-8

Immunotherapy for advanced renal cell cancer.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23613183